Infinity Gets More Than A Cash Boost With AbbVie Tie-Up
This article was originally published in The Pink Sheet Daily
Executive Summary
In a deal worth more than $800 million, AbbVie injects a vote of confidence into Infinity’s late-stage PI3K inhibitor program, but leaves the biotech the freedom to conduct other partnerships.
You may also be interested in...
Deal Watch: Merck Hopes Moderna's Personalized Vaccines Can Increase Keytruda Patient Base
Novartis and Xencor sign wide-ranging immuno-oncology collaboration targeting multiple CD pathways. Teva signs divestment agreements with five firms during June to meet FTC requirements for its acquisition of Allergan's generics business.
Infinity Doesn't Sugarcoat Disappointing Duvelisib Data
Infinity's hopes for accelerated approval of the PI3K inhibitor based on the DYNAMO study have been dashed, so while it plots a new strategy – with or without partner AbbVie – it cuts discovery R&D staff.
Infinity Gears Up For Duvelisib Filing, But Differentiation Still A Challenge
Duvelisib is on track for parallel filings for CLL and iNHL in 2016, but the company still has work to do in differentiating the PI3 kinase inhibitor, which it says could come through additional studies beyond pivotal trials.